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ABSTRACT
Aims: Currently, there is no consensus on
which form of insulin to use when initiating
insulin in type 2 diabetes (T2D). Our aim was
to compare glycated hemoglobin (HbA1C)
reduction, weight change and severe
hypoglycemia rates during the first year after
initiation of intermediate-acting insulin
isophane, insulin glargine and pre-mixed
insulin in patients with T2D.
Methods: Electronic clinical records of patients
with T2D, starting insulin at a tertiary referral
center in Auckland, New Zealand, from January
1 to December 31, 2012, were retrospectively
evaluated. Primary outcomes were HbA1C
reduction at 12 months and number of
hospital admissions for hypoglycemia.
Results: Of 339 eligible patients, 273 (80.5%)
started on intermediate insulin, 24 started on
insulin glargine and 42 started on pre-mixed
insulin. The mean HbA1C at insulin initiation
was 89–95 mmol/mol, but had decreased at
12 months by 26.6 mmol/mol with insulin
glargine, 23.4 mmol/mol with pre-mixed insulin
and 16.6 mmol/mol with insulin isophane
(p\0.05 vs. baseline for all groups). Patients on
insulin glargine were more likely to achieve the
HbA1C target of \55 mmol/mol compared with
patients on insulin isophane (16.7% vs. 4.8%;
p = 0.04). Persistence rates were higher in patients
initiated on pre-mixedinsulinvs. insulin isophane
(90.5% vs. 69.6%; p = 0.01). After controlling for
confounding variables, glargine was more likely to
achieve an HbA1C target of\55 (p = 0.05).
Conclusions: All insulin types caused a
significant reduction in HbA1C, but very few
met HbA1C targets. Insulin isophane was the
most common type of insulin prescribed at
initiation, with comparable outcomes to other
types of insulin. More observational studies are
needed to explore the possible impact of using
other insulin types at initiation.
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INTRODUCTION
Type 2 diabetes (T2D) is a disease characterized
by progressive beta cell decline [1]. Few oral
antidiabetic drugs preserve beta cell function,
therefore, 5–6% of all patients with T2D
progress to requiring insulin injections every
year worldwide [1]. Insulin therapy is associated
with a significant and persistent reduction of
glycated hemoglobin (HbA1C) across all groups.
Starting insulin reduces microvascular and
macrovascular complications in T2D [2].
Guidelines from the International Diabetes
Federation (IDF) recommend that patients
start on insulin when they have an HbA1C in
excess of 65 mmol/mol on dose-optimized oral
hypoglycemic therapy [3], but in reality many
patients do not start insulin until their HbA1c
level is far in excess of this threshold. In
addition, there is a lack of consensus between
guidelines on the optimal approach to initiating
insulin. The IDF guidelines recommend starting
with a long-acting basal insulin analog, with
pre-mixed insulin for those with higher HbA1C.
In contrast, the UK National Institutes
of Clinical Excellence (NICE) guidelines
recommend human insulin, based principally
on cost considerations, rather than any
apparent benefit seen in clinical trials [4].
Beginning with the addition of biphasic,
prandial, or basal insulin to oral therapy in
type 2 diabetes (4T) trial (trial number
ISRCTN51125379) in 2007 [5], there have been
several randomized control trials on insulin
initiation in T2D for patients on dose-optimized
oral hypoglycemic therapy [5–7]. These all trials
share many similarities, including similar
limitations. All are open-label trials, often
comparing a basal analog/intermediate-acting
insulin with prandial insulin and mixed insulin,
many share the same endpoints, and a
significant proportion are non-inferiority trials.
Insulin is most often commenced for patients in
primary care, where protocols on insulin
initiation differ markedly to trial protocols. In
clinical trials, insulin dose adjustment can be
patient- or physician-controlled and based on a
strict titration guideline in response to regular
blood sugar testing. In contrast, in clinical
practice, physicians are mostly responsible for
dose titration. The frequency of follow-up and
adherence to treatment and diabetes self-
management is much higher in clinical
studies, and cannot be replicated in everyday
practice. Therefore, in clinical trials, the
outcomes of insulin initiation often differ
markedly to those reported in large
observational studies of clinical practice.
Large cohort and observational studies allow
one to see the outcomes of insulin initiation in
a real-world setting. Observational studies also
have less stringent inclusion criteria and often
include patients with end-organ dysfunction
that trials would normally exclude. In the First
Basal Insulin Evaluation (Fine ASIA) study, most
patients initiating insulin therapy had had
diabetes for 9 years [8]. Most of these patients
had severe hyperglycemia and concomitant
microvascular complications. The mean
HbA1C reduction was around 1.5% [8], similar
to figures from other large cohort studies such
as the A1chieve study [9]. This amount of
HbA1C reduction was similar across all groups
regardless of the type of insulin used. In
observational studies, starting or switching to
insulin analogs was associated with low rates of
hypoglycemia and low weight gain [8, 9].
The aim of this study was to evaluate the
process and clinical outcomes of insulin
initiation in a real-world clinical scenario in
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New Zealand. HbA1C lowering efficacy and
rates of meeting a predetermined HbA1C
target, weight change and severe
hypoglycemia rates requiring hospital
admission at 1-year post-insulin initiation
were evaluated. In addition, the influence of
patient factors, such as HbA1C at initiation,
duration of T2D, age and ethnicity on the
physician’s choice of insulin was evaluated.
METHODS
Study Design
A retrospective analysis of the electronic
medical records from patients with T2D,
attending the tertiary clinical center at the
Auckland District Health Board between
January 1, and December 31, 2012 was
conducted. The following data were collected
at the initiation of insulin therapy and 1 year
later: patient demographics, anthropometric
data, microvascular and macrovascular
complications at the time insulin initiation,
details of hospital admissions for hypoglycemia
in the 12 months after insulin initiation,
change in weight, persistence with prescribed
insulin and whether patients achieved the
predetermined HbA1C target of\55 mmol/mol.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
Patient Selection
The Auckland District Health Board catchment
area has 469,000 patients of which 5% are
affected by T2D (Wijayaratna, personal
communication). It is one of three autonomous
district health boards that is responsible for
providing healthcare services to the 1.4 million
patients in the Auckland Metropolitan area.
Included in the study were patients who had
been referred for a review of their diabetes care by
the duty nurse specialist at the tertiary clinical
center, and who were initiated on insulin in
2012. Patients are referred to the clinical center
from the Auckland Public Hospital (inpatient
services), retinal screening programs, medical
specialists or primary care.
All patients with T2D referred to the duty
nurse specialist for the first time underwent
comprehensive nutrition and self-management
session, including the appropriate use of insulin
and oral hypoglycemics as required. Written
information and links to useful websites were
also provided.
The decision to commence patients on
insulin was taken in the course of normal
clinical practice. All patients were initiated on
one of three types of insulin: intermediate-
acting insulin isophane (human neutral protein
Hagedorn) twice daily or at night, biphasic
human insulin (pre-mix) twice daily or long-
acting once-daily insulin analog (glargine).
These were the three commercially available
insulin types that were subsidized by
Pharmaceutical Management Agency
(PHARMAC), the New Zealand drug-buying
agency [10]. PHARMAC is a Crown entity
established by the New Zealand Health and
Disability Act 2000 and directly accountable to
the Minister of Health [10]. The patient and
diabetes clinicians together negotiated the
choice of insulin, the starting dose,
administration frequency and any later
changes to dose or titration frequency.
Excluded from the study were patients with
type 1 diabetes, new-onset diabetes after
transplantation, steroid-induced diabetes, or
latent autoimmune diabetes. In addition, the
study excluded patients with T2D who were not
started on insulin, and those without electronic
medical records on insulin commencement.
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Figure 1 gives an overview of the patient
selection process.
Study Endpoints
The primary outcomes were the proportion
of patients achieving an HbA1C of \55
mmol/mol, rates of hospital admission for
hypoglycemia, and weight change. These were
analyzed on an intention to treat basis.
A patient was admitted to hospital if their
blood sugar levels were less than 2.5 mmol, if their
hypoglycemia was associated with a loss of
consciousness defined as a Glasgow Coma
Scale \12 or if they required intramuscular or
intravenous glucose to relieve their symptoms.
The purpose of admission was further monitoring
and addressing the cause of hypoglycemia.
As secondary outcomes, factors that may
influence physician choice of insulin at
initiation were analyzed. Following the results
of the A1chieve study [9], measurements of
microvascular complications at baseline were
taken, as well as duration of diabetes.
All the HbA1C results in the Auckland District
Health Board were analyzed using a Siemens/
Bayer AG 2000? analyzer (Bayer AG, Leverkusen,
Germany) using the high-performance liquid
chromatography method. The assay was
Diabetes Control and Complications Trial
aligned with a coefficient of variance of less
than 5% (personal communication). The range of
values was 4–130 mmol/mol and normal values
are quoted as 40–60 mmol/mol. An HbA1c target
of 55 mmol/mol was used based on the New
Zealand primary care handbook 2011 target for
optimal control [11].
Statistical Analysis
Statistical analysis was performed by comparing
the proportions as samples using Fisher’s exact
test as a non-parametric test and by performing
multiple logistic regression with HbA1C
\55 mmol/mol and hospital admission for
hypoglycemia as outcome measures. Age,
duration of diabetes, ethnicity and dose of
insulin were dependent variables. A
multivariate logistic regression was used to fit
a model that examined the primary outcomes.
The first model examined the relationship
between achieving HbA1C \55 mmol/mol
(binary outcome) and age, ethnicity, duration
of diabetes, and type of insulin used. The
second model examined the same variables
and their relationship to hypoglycemia.
The Kruskal–Wallis test was used to compare
paired HbA1C data pre- and post-insulin
initiation for those with an HbA1C
[85 mmol/mol. This was appropriate as the
samples were not normally distributed.
Missing data were analyzed as zero values.
Patients who had changed insulin therapy
during the follow-up period did not have their
values included for dose change of each insulin
type. Statistical analysis was carried out using
SPSS version 21.0 for Microsoft Windows
platform. (SPSS Inc. Chicago, IL, USA).
RESULTS
Patient Characteristics
A total of 339 patients met the inclusion
criteria. At 12 months following initiation,
follow-up data were available on all (100%) of
these patients. Those that did not have
electronic follow-up data had already been
excluded (Fig. 1).
The baseline characteristics of those
commenced on insulin are shown in Table 1.
Of these, 273 (80.5) were commenced on
intermediate-acting insulin isophane, 24
(7.1%) were commenced on long-acting
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insulin glargine once daily, and the remaining
42 (12.4%) patients were commenced on
biphasic pre-mixed insulin.
The mean age was 55.7 years in the insulin
isophane group, 59.2 years in the glargine group
and 56.7 years in the pre-mixed group. There
was no statistically significant difference in age
distributions between the three groups. There
was also no statistically significant difference in
terms of weight or BMI between the three
groups (see Table 1).
Europeans (36%) and Pacific Islanders (32%)
were the two largest ethnic groups of patients
commenced on insulin. The remaining patients
Fig. 1 Selection of eligible patients. LADA Latent autoimmune diabetes, NODAT new-onset diabetes after transplantation,
T1/2D type 1/2 diabetes
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were of Asian (23%), Maori (5%) or other (4%)
ethnicity.
The only statistically significant differences
between groups at baseline were that those
commenced on pre-mixed insulins were less
likely to be on sulfonylureas than those started
on intermediate insulin (31.0% vs. 68.1%,
p\0.0001, Fisher’s exact test) (see Table 1),
and those on pre-mixed insulin had a higher
rate of retinopathy compared to those on
intermediate-acting insulin (48.8% vs. 20.8%;
p = 0.0001). The rates of all microvascular
complications were higher in the pre-mixed
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Male 139 (50.9) 15 (62.5) 21 (50.0)


























Oral hypoglycemic agents, n (%)
Metformin 210 (76.9) 16 (66.7) 33 (78.6)
Sulfonylurea 186 (68.1) 17 (70.8) 13 (31.0)
Other 10 (3.7) 3 (12.5) 1 (2.4)
BMI body mass index, SEM standard error of the mean
a p = 0.013 vs. intermediate-acting insulin isophane
b p\0.05 vs. intermediate-acting insulin isophane
Table 2 Primary and secondary outcome measures
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11 (4.0) 0 5 (11.9)
HbA1c glycated hemoglobin, SEM standard error of the
mean
a p = 0.04 Fisher’s exact test vs. isophane
b p = 0.01 Fisher’s exact test vs. isophane
54 Diabetes Ther (2015) 6:49–60
group than those on intermediate-acting
insulin and insulin glargine.
HbA1C Lowering
There was a statistically significant reduction in
HbA1C at 1-year post-initiation of insulin across
all insulin modalities. This was greatest for long-
acting insulin glargine (HbA1C reduction from
95.4 to 68.9 mmol/mol; p\0.0001, Student’s
t test), followed by biphasic pre-mixed insulin
(HbA1C reduction from 93.7 to 70.0 mmol/mol;
p = 0.0045) and intermediate-acting insulin
isophane (HbA1C reduction from 89.3 to
72.7 mmol/mol; p = 0.0001) (Table 2).
There was no significant difference between
the three groups in the amount of HbA1C
lowering at 1 year.
Twenty of the 339 patients (5.9%) met the
predetermined HbA1C target of \55 mmol/mol
at 1-year post-insulin initiation. Overall, 13
patients in the intermediate insulin group, 4
patients in the glargine group and 3 patients in
the pre-mixed group met these targets. Those
on insulin glargine were more likely to meet the
HbA1C target than those on intermediate-
acting insulin (p = 0.038, Fisher’s exact test).
In a subgroup of 146 patients with an HbA1C
of [85 mmol/mol at insulin initiation, pre-
mixed insulin was associated with a greater
proportional reduction in HbA1C (Table 3).
There was no statistically significant difference
in the amount of HbA1C lowering between the
three groups (p = 0.272, Kruskal–Wallis test).
Dose Increases
Those on insulin isophane and insulin glargine
were started on an average dose of 0.2 U/Kg (15
and 19 units, respectively). Those on pre-mixed
insulin were started on 0.3 U/kg (31 units).
After 1 year, there was only a modest dose
increase 0.1 U/kg in the dose of insulin
isophane or glargine and a 0.2 U/kg increase in
pre-mixed insulin.
Persistence Rates
Overall, 190 of the 273 patients commenced on
intermediate insulin continued using the same
type of insulin at 1 year (69.6%) compared to 20
of 24 on long-acting insulin glargine (83.3%)
and 38 of 42 (90.5%) on biphasic pre-mixed
insulin. Those on pre-mixed insulin were more
likely to continue using the same type of insulin
compared with those on intermediate-acting
insulin (p = 0.01, Fisher’s exact test). There was
no statistically significant difference in the
persistence rate between those commenced on
insulin glargine and intermediate insulin
(p = 0.241, Fisher’s exact test).
In the subgroup of patients who persisted on
intermediate-acting insulin, 96 (50.5%) stayed
on once-daily intermediate insulin, 74 (38.9%)
changed to twice-daily intermediate insulin
from once-daily intermediate insulin, and
20 (10.5%) were started on twice-daily
intermediate insulin.
Of those who did not persist on insulin for
1 year, 62 of 83 patients who were initiated on
intermediate isophane insulin were changed to
pre-mix, 14 to insulin glargine and 7 to basal
bolus. Among those started on insulin glargine,
two were changed to basal bolus and two to pre-
Table 3 Odds of achieving HbA1C\55
Variable Odds ratio
(95 % conﬁdence intervals)
p value
Glargine insulin 3.7 (1.0, 14.1) 0.05
Pre-mixed insulin 1.9 (0.5, 7.4) 0.37
Isophane 1.0
HbA1c glycated hemoglobin
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mixed insulin. Of the patients who were
initiated on pre-mixed insulin, an equal
number changed to insulin glargine and
intermediate insulin.
Hypoglycemia
There were 16 hospital admissions for
hypoglycemia at 1-year post-initiation of
insulin (Table 2). Eleven hospitalizations were
for patients initiated on intermediate insulin
and five for patients on pre-mixed insulin.
Patients initiated on insulin glargine did
not develop hypoglycemia requiring
hospitalization; however, this finding was not
statistically significant (p = 0.6093, Fisher’s
exact test). There was no correlation between
type of insulin and hypoglycaemia rate,
p = 0.465, fisher’s exact test.
Weight Gain
The mean weight gain across all three groups
was comparable and there was no statistically
significant difference between the three groups
(Table 2). Patients on intermediate-acting
insulin gained on average 1.9 kg, those on
insulin glargine 1.1 kg and those on pre-mixed
insulin gained 0.9 kg.
Follow-Up Rates
Overall, 33.9% of patients started on insulin
were followed up at 1 month and 63.3%
followed up at 3 months. In the isophane
insulin group, 39.6% were followed up at
1 month, and 65.6% followed up at 3 months.
Follow-up rates were lowest in patients on pre-
mixed insulin, with 21.3% of patients followed
up at 1 month, and 58.3% at 3 months. Of
those on insulin glargine 33% were followed up
at 1 month and 71.4% followed up at 3 months.
There was no significant difference in the
HbA1C of groups with differing frequencies of
follow-up at 1 year. The HbA1C outcomes
arranged by follow-up duration are as below.
Logistic Regression
A binomial logistic regression model was
constructed to explain variation in the rates of
achieving the primary outcome HbA1C \55
mmol/mol, including age, ethnicity, starting
and ending dose of insulin, and the presence of
3-month follow-up. The model had an R2 value of
0.2 indicating that it was moderately predictive.
A similar model for patients at risk of
hypoglycemia was constructed using the same
variables, and found no significant difference
between the three insulin groups. Compared to
isophane insulin, neither glargine (odds ratio
[OR] 0.9) nor pre-mixed insulin (OR 0.87) was
associated with a significantly different rate of
hypoglycemia.
DISCUSSION
In this retrospective cohort study, the efficacy of
the three most commonly used insulin
modalities used to initiate therapy in insulin-
naı¨ve patients with T2D was evaluated. A
statistically significant reduction in HbA1C
was achieved in the 12 months after insulin
initiation, regardless of the type of insulin used.
The mean reduction in HbA1C was between 17
and 27 mmol/mol in all groups. This study was
an open-label, retrospective study conducted in
a true clinical setting that chose to analyze
clinically relevant endpoints.
In this New Zealand cohort of T2D patients,
intermediate-acting insulin isophane was the
most common type of insulin initiated.
Physician factors known to impact on insulin
choice include cost, availability, efficacy, and
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local clinical practice guidelines, as well as
patient preference. There is a significant
worldwide variation in the type of insulin
prescribed first-line [12]. In the Southeast
Asian cohorts of the Novo Nordisk-funded
A1chieve study, more than 75% of patients
were prescribed a pre-mixed insulin as their
initial insulin, whereas in the rest of the world
basal insulin was prescribed to the majority of
insulin-naı¨ve patients [9]. This choice may be
influenced by local factors such as diet, as a
high-carbohydrate diet with increased
postprandial blood sugars may prompt more
use of a regimen containing some form of short-
acting insulin.
The choice of therapy may also be influenced
by local medical practice. In a New Zealand
context, PHARMAC manages the
pharmaceutical schedule, and is responsible
for the optimal use of medications and the
allocation of subsidies for each medication or
medication type [13]. The decision to fund a
new medication is one that involves two
subcommittees of PHARMAC, the
Pharmacology and Therapeutics Advisory
committee, representing clinical interests, and
the Consumer Advisory Committee broadly
representing consumer interests [10].
Guidelines play a vital role in influencing
physician choice; the New Zealand primary
care handbook recommends the use of
isophane insulin at night and isophane insulin
twice daily as first- and second-line treatments,
respectively, for patients with T2D requiring
insulin [11]. It is used as a reference by
physicians in training as well as specialists in
hospital [11]. A more carbohydrate-rich diet
with increased postprandial blood sugars may
prompt use of a regime containing some form of
short-acting insulin.
Patient factors that influence insulin choice
include fear of injection, fear of complex insulin
regimens as well as fear of hypoglycemia and
weight gain [12]. The 4T trial found that basal-
only insulin was associated with less weight
gain and fewer episodes of hypoglycemia
compared with short-acting insulin regimens
[4]. From both of these points of view, one can
appreciate that intermediate-acting insulin has
benefits as a first-line insulin therapy, but the
efficacy may be less than that of other agents.
Patients initiated on insulin glargine were
more likely to meet HbA1C targets, having
adjusted for other confounding variables, and
did not have hypoglycemic events requiring
hospitalization in the 1-year post-insulin
initiation. Several trials have found an
increased chance of meeting HbA1C targets
and low rates of all hypoglycemia, especially
nighttime hypoglycemia in those commenced
on insulin glargine [2, 5, 7]. While the low rates
of hypoglycemia may be due to the peak-less
mechanism of action, the Monnier hypothesis
may help to explain effectiveness of insulin
glargine in lowering HbA1C [14]. As HbA1C
rises, the proportional contribution of fasting
sugars to HbA1C increases, and as a result those
on basal insulin should have a greater
proportional lowering of HbA1C [14]. In the
small group of patients commenced on glargine
in the preset study, patients were more likely to
persist on insulin therapy than intermediate
insulin, possibly due to the once-daily use of
glargine as opposed to twice-daily use of
isophane. These factors need to be explored
with further, larger observational studies.
Patients initiated on pre-mixed insulin had
more microvascular complications at baseline,
were more likely to persist with insulin and
there was greater proportional reduction of
HbA1C in those with high HbA1C. Data from
the Algerian cohort of the A1chieve study,
found that pre-mixed insulin was more often
prescribed with those with poor glycemic
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control and increased incidence of
microvascular complications [12].
Although intermediate insulin was the most
commonly initiated insulin, only 69% of
patients persisted on intermediate insulin at
1 year. More patients were likely to persist on
insulin glargine, and even more still persisted
on pre-mixed insulin in a statistically
significant manner. In a large observational
study based on US insurance claims, more
patients persisted on insulin glargine in a
statistically significant manner than other
insulins [15]. Insulin glargine is usually
initiated once daily, and most patients persist
on once-daily regimens, whereas up to 40% of
intermediate insulin patients have changed to
twice-daily administration at 1 year [15]. This
ease of administration with fewer injections
may be a major contributing factor in more
patients persisting with insulin glargine. The
increased persistence of pre-mixed patients is
unusual, and not widely documented in the
literature [16]. In the local practice where this
study was based, pre-mixed is generally
instituted third line following once- and twice-
daily basal insulin. Patients may be more keen
to persist with it due to the absence of other
viable insulin therapy, with the exception of
basal bolus (too many injections) and insulin
pump therapy which is not commonly used in
New Zealand for T2D [11].
The study limitations included retrospective
nature of the study and small sample size. This
might have had a particular impact on both the
insulin glargine and pre-mixed insulin groups
where small sample size impeded the ability to
detect known associations such as reduced rates
of hypoglycemia with insulin glargine. An
underlying cause could be selection bias, as
insulin glargine was not subsidized for use in
New Zealand for T2D until 2010 [17]. Even
when it was subsidized for use it was used
primarily in patients with a high perceived risk
of hypoglycemia. The use of insulin glargine as
a first-line agent is becoming more widespread
not only because of its low rates of
hypoglycemia, but also because of its single-
dose regimen, peak-less mechanism of action
that ensures a flexibility of delivery time that is
not available in standard human insulin [18].
The sample of acute referral patients in the
present study may be a separate group than
those outpatients treated in a standard way by
medical and nursing specialist at the center.
Finally another major limitation is the lack of
patient satisfaction input and use of quality-of-
life indicators. A recent follow-up from the
A1chieve study has shown that patients had a
statistically significant improvement in their
quality of life upon starting or switching to
long-acting analogs [19]. Further studies would
have to address these and other limitations to
gain more generalizability.
In a publically funded system, the cost
effectiveness of any intervention should be
considered. In New Zealand, the cost of a
300-unit vial of glargine ($100) is greater than
that of the most commonly used pre-mixed
insulin, Penmix 30 (Novo Nordisk
Pharmaceuticals, Pakuranga Auckland, New
Zealand) ($42.67) with isophane being the
cheapest of the three ($28) [20]. Given that there
is no overall difference in mean HbA1C lowering
between the three groups, it may be more cost
effective to consider isophane insulin as the
preferred initiation insulin [20]. These value
judgments must be made on a case-by-case basis.
This retrospective cohort study found that,
at a clinical center in New Zealand, insulin is
initiated in patients with T2D at a higher
HbA1C threshold than it is in randomized
controlled trials. Moreover, in clinical practice,
patients who start insulin often have pre-
existing microvascular and macrovascular
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complications, and would therefore be excluded
from many clinical trials. Initiating any insulin
in this group, regardless of type, resulted in
statistically significant reductions in mean
HbA1C. Patients on insulin glargine were more
likely to achieve HbA1c targets and did so with
no hypoglycemic episodes in the 12-month
follow-up period. Those who commenced on
pre-mixed insulin had a higher rate of
complications at outset but were more likely
to persist on insulin therapy, with the
suggestion of added benefit at higher HbA1C.
The data suggest that, in clinical practice, most
patients with T2D can be initiated on insulin
glargine, but those with multiple pre-existing
microvascular complications and very poor
glycemic control may be initiated on pre-
mixed insulin to achieve better glycemic
control and reduced morbidity from
complications. This model of insulin initiation
in clinical practice would need to be validated
in larger observational and interventional
studies.
CONCLUSION
Patients in the present study commenced on
insulin at a much higher HbA1C than those in
clinical trials. All types of insulin provided a
statistically significant HbA1C reduction at
1 year. Insulin isophane was the most
common type of insulin initiated but it had
comparable results to all other insulin types.
Patients had a high rate of poor glycemic
control, indeed few patients met the
predetermined glycemic targets following
1 year of insulin therapy. Other types of
insulin have some promising characteristics,
although the subgroup sample size is too small
to allow meaningful analysis.
While the optimal insulin initiation regimen
in clinical practice has not yet been defined,
these results highlight the importance of
starting insulin (of any type) to achieve
glycemic targets in patients with T2D and
microvascular and macrovascular
complications. Given the current and future
burden of T2D in New Zealand, as in other
developed countries, urgent action is needed to
overcome therapeutic inertia, and thereby
to limit wherever possible the humanistic
and financial burden of diabetes-related
complications.
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